Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Nectar Lifesciences Ltd. Share Price
Day's Range
Day's Range
Low
₹12.25
High
₹13.30
Price Summary
| Previous Close | ₹12.38 |
|---|---|
| Day's Range | ₹12.25 - ₹13.30 |
| Open | ₹12.70 |
| 52 Week Range | ₹09.30 - ₹28.25 |
| Volume | 2,19,065 |
| Market Cap | ₹0.00 |
| Previous Close | ₹12.01 |
|---|---|
| Day's Range | ₹11.98 - ₹12.70 |
| Open | ₹12.70 |
| 52 Week Range | ₹09.20 - ₹28.27 |
| Volume | 39,699 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 27.12 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -18.28 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 0.35 |
| PAT Margin (%) | -5.96 |
| Face Value (₹) | 1.00 |
| ROCE(%) | -5.21 |
| Trade Value ( ₹ in Lacs) | 4.77 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -18.28 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 0.35 |
| PAT Margin (%) | -5.96 |
| Face Value (₹) | 1.00 |
| ROCE(%) | -5.21 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 0.06 | 16856.32 |
| Expenses | N/A | N/A |
| PBT | 3.52 | 182.69 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 78.4 | 49.95 |
About Nectar Lifesciences Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | Sanjiv Goyal |
| NSE Symbol | NECLIFE |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,51,074.97 | 1,905.20 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,485.96 | 6,818.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,124.14 | 4,394.35 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,201.01 | 8,028.70 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,640.69 | 1,426.60 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,11,589.46 | 1,329.30 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,966.32 | 2,248.00 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,03,368.09 | 2,504.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,02,190.60 | 1,060.00 | 903.00 - 903.00 |
| Zydus Lifesciences Ltd. | 1,01,755.41 | 991.20 | 835.50 - 835.50 |
No Records Found
Latest News
Nectar Lifesciences informs about compliance report
Nectar Lifesciences informs about minutes of ordinary and special resolutions
Nectar Lifesciences informs about disclosures
Nectar Lifesciences informs about outcome of board meeting
Nectar Lifesciences has informed that the board of directors of the company in their meeting held on Monday, March 02, 2026, have, noted, decided and approved the following matters: 1. To acquire 100% paid- up equity share capital of Avensis Exports (‘AEPL’). 2. Change in Registrar and Share Transfer Agent (‘RTA’) of the Company from KFin Technologies (‘KFIN’) to Alankit Assignments (‘AAL’). KFIN will continue to serve as the Company’s RTA until the completion of data transition, shifting of electronic connectivity, and other related procedures, along with receipt of necessary confirmations from NSDL and CDSL. The formalities for change of RTA including documentation, execution of agreement, shifting of electronic connectivity and transition of data will be done by the Company in due course. The details as required under LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and as amended upto date, are provided in: 1. Annexure A for Acquiring 100% paid- up equity share capital of AEPL; and 2. Annexure B for change in RTA from KFIN to AAL. The Board Meeting commenced at 04:00 pm IST and concluded at 04:30 pm IST.
The above information is a part of company’s filings submitted to BSE.
FDC informs about board meeting
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Nectar Lifesciences Ltd. is ₹12.38 as of 2026-05-18.
The market capitalisation of Nectar Lifesciences Ltd. is ₹244.96 as of 2026-05-15.
The 1-year return of Nectar Lifesciences Ltd. is -0.32% as of 2026-05-18.
The P/E ratio of Nectar Lifesciences Ltd. is 0.00 as of 2026-05-18.
The 52-week high and low of Nectar Lifesciences Ltd. are ₹28.25 and ₹9.30, respectively, as of 2026-05-18.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
